 Altimmune stock was trading lower after the release of positive results, achieving both primary and secondary endpoints of phase 1b study with pemvidutide in NASHobese patients provides a buying opportunity. It provided updated 24-week results from phase 1b study using pemvidutide in NASHobese patients measuring weight loss expected Q4 of 2022. 